PMC:7534795 / 45482-45766 5 Projects
Annnotations
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T389 | 65-242 | Sentence | denotes | • Secondary outcome includes reduction of IL-6 levels • Eicosapentaenoic acid free fatty acid (EPA-FFA) 1 g gastro-resistant capsules twice daily (2 g total) (NCT04335032, 2020) |
| T390 | 243-260 | Sentence | denotes | • COLCORONA Trial |